| 
			
			 Greece legalised cannabis for medical use last year and in March 
			lifted a ban on growing and producing it. Two licences were granted 
			on Monday, and another 12 will be issued by the end of this year, 
			the Economy and Development Ministry said. 
 "There is huge interest, mainly from Canada and Israel ... some of 
			them (potential investors) are huge," Stergios Pitsiorlas, the 
			deputy economy minister, told a news conference.
 
 Legalising cannabis for recreational purposes is not under 
			consideration, Pitsiorlas said in response to a question.
 
			
			 
			
 Pitsiorlas said the first medicinal cannabis products were expected 
			to hit the market in about 12-18 months time. The industry was 
			mainly export-oriented, he said.
 
 Thousands of patients in Greece are thought to use cannabis for a 
			range of serious medical conditions, though authorities don't have 
			precise figures.
 
 Several countries, including Britain, Germany, Italy and Denmark, 
			already allow the prescription of medicinal cannabis, and in June 
			Canada became the second country in the world, after Uruguay, to 
			fully legalise marijuana, ending a 90-year ban.
 
			
            [to top of second column] | 
 
			Under Greece's licensing system, medicinal cannabis products would 
			be available on prescription from chemists. It would not be 
			subsidised through state health insurance schemes, Health Minister 
			Andreas Xanthos said.
 The first licensed cannabis hothouses will be in Larisa in central 
			Greece, and in Corinth in the Peloponnese. The 14 licences were 
			expected to create more than 750 jobs and represented about 185 
			million euros ($212.05 million) in investment.
 
 "Our message is that the country is open for investments," said 
			Vassilis Kokkalis, deputy minister of agriculture.
 
 (Reporting by Lefteris Papadimas; Editing by Mark Heinrich)
 
			[© 2018 Thomson Reuters. All rights 
				reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			
			 |